Since
infection develops in significant numbers of hospitalized patients, the problem of resistance to
third-generation cephalosporins is of increasing concern. We evaluated the efficacy of
cefepime 1 g bd as treatment for acute, moderately severe
bacterial infection in 239 hospitalized patients (mean age 60 years). Of these patients, 204 were evaluated clinically for
urinary tract infection (UTI) (n = 90), lower
respiratory tract infection (LRTI) (n = 70), skin and
soft tissue infection (S/
STI) (n = 12) and bacteraemia which was associated with either UTI or LRTI (n = 32) but not included in the previously mentioned UTI and LRTI groups. Amongst the pathogens isolated (36 Gram-positive, 150 Gram-negative), the most predominant species were Escherichia coli in UTI and bacteraemia (n = 81), Streptococcus pneumoniae in LRTI and bacteraemia (n = 23), Haemophilus influenzae in LRTI (n = 16), Pseudomonas aeruginosa (n = 4) and Enterobacter cloacae (n = 2) in S/
STI. The mean
duration of treatment was 8.5 days and was the same for the 204 clinically evaluable patients. Overall, the clinical cure rate for
cefepime was 94% (191/204). Pathogen eradication was achieved in 93% (185/199) of
infections. Of the patients with associated bacteraemia, the clinical cure rate was 97% (31/32) and 94% (16/17) of the pathogens were eradicated.
Cefepime therapy was well-tolerated. Treatment was discontinued in eight patients (3%) because of local intolerance and in five patients (2%) because of
drug-related adverse events (
rash,
headache and
pruritus).
Cefepime 1 g bd is as safe and effective as other parenteral
cephalosporins for the treatment of acute bacterial UTI, LRTI and S/
STI, including those cases with associated bacteraemia. The bd dosing schedule and reported lack of cross-resistance with other
cephalosporins against some species of aerobic Gram-negative bacilli make
cefepime an attractive treatment option in hospitalized patients.